Our recent publications - highlights

2017

Autism spectrum and psychosis risk in the 22q11.2 deletion syndrome. Findings from a prospective longitudinal study

Fiksinski AM, Breetvelt EJ, Duijff SN, Bassett AS, Kahn RS, Vorstman JA: Schizophr Res. 2017 Jan 21. pii: S0920-9964(17)30044-0. doi: 10.1016/j.schres.2017.01.032. [Epub ahead of print]

This research investigated whether Autism Spectrum Disorders (ASDs) in individuals with 22q are actually associated with an increased risk for development of schizophrenia, or whether psychotic disorders and ASDs may arise independently. The answer was that they are independent conditions.

Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease

Butcher NJ, Marras C, Pondal M, Rusjan P, Boot E, Christopher L, Repetto GM, Fritsch R, Chow EW, Masellis M, Strafella AP, Lang AE, Bassett AS. Brain (2017) Mar 24. (doi: 10.1093/brain/awx053)

See the UHN Research News article

This research explored signs and symptoms in adults with 22q11.2 deletion syndrome that may be related to a risk of developing Parkinson's disease, a treatable movement disorder that affect some older adults. By using a combination of clinical assessments and brain imaging, we found new evidence that adults with 22q11.2 deletion syndrome may have problems with movements and may also have differences in dopamine, a brain chemical that can affect the way we move and feel. These results may help us better understand conditions that affect adults with 22q11.2DS, such as Parkinson's disease and schizophrenia.

Obesity in adults with 22q11.2 deletion syndrome
Voll SL, Boot E, Butcher NJ, Cooper S, Heung T, Chow EW, Silversides CK, Bassett AS: Genet Med. 19(2):204-208, 2017. (doi: 10.1038/gim.2016.98)

This study compared the heights and weights of adults with 22q to the Canadian population. Starting in the 19-24 age group, on average people with 22q had higher rates of obesity whether they were or were not taking medications that can increase the risk for weight gain.

[Return to top]

2016

The importance of copy number variation in congenital heart disease
Costain G, Silversides CK, Bassett AS.
Genomic Medicine (2016) 1, 16031; (doi:10.1038/npjgenmed.2016.31); published online 14 September 2016

This review article looked at the contribution of genome-wide rare copy number variation (CNV) to congenital heart disease (CHD). Prevalence of CHD in people with CNV was discussed, as well as clinical and research advances paving the way for whole-genome sequencing to understand the genetic basis for CHD in the future.

Internet Safety Issues for Adolescents and Adults with Intellectual Disabilities.
Buijs PC, Boot E, Shugar A, Fung WL, Bassett AS.
J Appl Res Intellect Disabil. 2016 Feb 23. (doi: 10.1111/jar.12250). [Epub ahead of print]

This brief report looked at some potential challenges of internet safety for adolescents and adults with 22q. Examples of particular dangers were presented, and safety interventions and next steps for doctors and clinicians were discussed.

[Return to top]

2015

22q11.2 deletion syndrome
McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, Zackai EH, Emanuel BS, Vermeesch JR, Morrow BE, Scambler PJ, Bassett AS. (2015) Nature Reviews Disease Primers 1:15071. doi: 10.1038/nrdp.2015.71.

Response to clozapine in a clinically identifiable subtype of schizophrenia: 22q11.2 deletions mediate side effect risk and dosage.

Butcher NJ, Fung WLA, Fitzpatrick L, Guna A, Andrade D, Lang A, Chow EWC, Bassett AS: British Journal of Psychiatry 206:484-491, 2015 (doi:10.1192/bjp.bp.114.151837)

This research explored how individuals with 22q and schizophrenia respond to the medication clozapine, and how it differs from individuals with schizophrenia who do not have 22q. We found that a lower dose of clozapine and using preventative measures can help lower the risks of side effects for individuals with 22q.

Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome

Boot E, Butcher NJ, van Amelsvoort TAMJ, Lang AE, Marras C, Pondal M, Andrade DM, Fung WLA, Bassett AS: American Journal of Medical Genetics Part A 167:639-645, 2015 (doi:10.1002/ajmg.a.36928)

This research looked at five examples of adults with 22q who also had movement disorders, which could range from balance problems to shakiness. Through these examples, we were able to suggest common symptoms and possible causes of these disorders, which can help other health care professionals to provide better care for individuals with 22q.

Practical guidelines for managing adults with 22q11.2 deletion syndrome.

Fung WLA, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EWC, Chung B, Cytrynbaum C, Faghfoury H, Fishman L, García-Miñaúr r S, George SR, Lang AE, Repetto G, Shugar A, Silversides C, Swillen A, van Amelsvoort T, McDonald-McGinn DM, Bassett AS and the International 22q11.2DS Consortium: Genetics in Medicine 17:599-609, 2015 (doi:10.1038/gim.2014.175)

This review is a practice guideline for providing health care to adults with 22q. An international panel of researchers collaborated to contribute to this paper, with topics covering the management of psychiatric and medical conditions, as well as how to identify these conditions in adults with 22q.

[Return to top]

2014

Prevalence of hypocalcaemia and its associated features in 22q11.2 deletion syndrome

Cheung ENM, George SR, Costain GA, Andrade DM, Chow EWC, Silversides CK, Bassett AS: Clinical Endocrinology 81:190-196, 2014 (doi: 10.1111/cen.12466)

This research explored how common low calcium levels are in individuals with 22q, and what the possible causes are. We found that in addition to changes in parathyroid function, low thyroid function may also play a role in causing low calcium levels. Also, individuals with 22q can have low levels of magnesium, which can further lower calcium. Dietary intake such as pop and alcohol were also found to lower calcium levels, and reducing intake of these drinks is an important preventative strategy.

[Return to top]